Spectral AI’s Founder Rejoins its Board of Directors

Spectral AI Inc. has welcomed back J. Michael DiMaio, M.D., to its Board of Directors, appointing him to fill the vacancy left by board member Michael Murphy’s resignation.
 
DiMaio is one of the company’s founders and previously served as CEO and board chairman from 2011 to 2020. He left Spectral AI in 2020 and amicably resolved a dispute. He is currently the Chief of Staff and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest U.S. cardiovascular programs. The hospitals he oversees are rated with the highest quality scores by the Society of Thoracic Surgeons, Society of Vascular Surgery, and the American College of Cardiology. DiMaio supervises more than 650 physicians across six facilities that perform approximately 25,000 cardiovascular procedures annually.

“I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors,” Board Chairman Richard Cotton said. “Dr. DiMaio’s deep knowledge and application of medical device technologies, decades of direct patient care, and experiences within some of the United States’ preeminent medical systems and current leadership make him qualified to support the planned commercialization and ongoing development of our DeepView System.”
 
DiMaio earned his medical degree from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke University Medical Center and performed research under an NIH-sponsored grant. He has been elected to or served as a member of many medical organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American Association of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation, American Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.
 
DiMaio has authored nearly 500 peer-reviewed publications and abstracts, and directs a research group that has produced more than 1,000 publications in medical journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation. He has been an editorial board member or reviewer for some of the world’s most prestigious medical journals and has served as a grant reviewer for the National Institutes of Health (NIH), the American Heart Association, and the U.S. Department of Defense in an addition to serving on international medical guideline committees.
 
In clinical trials, DiMaio has been the principal investigator for numerous drugs and devices that have received U.S. Food and Drug Administration approval and commercialization. He has been awarded more than $150 million funding from the NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense, the Department of Health and Human Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees more than 120 clinical trials at the Baylor Scott & White Research Institute and chairs the Cardiovascular Research Review Committee for the healthcare system. 
 
“I have spent a great deal of my career developing technologies that improve patient outcomes while delivering tangible value across the healthcare spectrum and founded this company with the intent to fill the unmet clinical need for a decision-assist device to improve wound care management,” DiMaio stated. “I believe the company’s AI-driven wound imaging and assessment technology platform is poised to deliver on those objectives, and I am very pleased to be in a position to help advance this technology towards commercialization of current and future indication developments.”
 
The company also announced that DiMaio and Erich Spangenberg, who together hold approximately 45% of Spectral AI’s outstanding shares, have each agreed to an additional six-month extension of the current lock-up of their outstanding shares pursuant to the Registration Rights/Lock-Up Agreement.
 
Spectral AI Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The company is working to significantly improve the management of wound care with its DeepView System, a predictive diagnostic device that offers clinicians an immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.